Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
Year: 2018
Type: article
Study design: Clinical Trial
Abstract: Background: Combination treatment with PD-1 + CTLA-4 checkpoint inhibitors shows improvement in breadth, depth, and durability of response, coupled with a disproportionate increase in immune-related adverse events (irAE). CX-072, a Probody™ therapeutic (Pb-Tx) directed against PD-L1, is designed to be preferentially activated by tumor-associated proteases and not in healthy tissue. Preclinically, anti–PD-1 Pb-Tx + anti–CTLA-4 showed comparable efficacy with improved safety compared to the non–Pb-Tx combination control.
Source: Annals of Oncology
Institutions: Newcastle University, Providence Portland Medical Center, University Medical Center Groningen, Yale Cancer Center, Yale University, Sarah Cannon Research Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Rush University Medical Center, Hospital Universitario HM Sanchinarro, Hospital Clínic de Barcelona, CytomX Therapeutics (United States), Memorial Sloan Kettering Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Manchester, The Christie NHS Foundation Trust
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898149168